KRAS and intrahepatic cholangiocarcinoma: Previous studies have already revealed that activating mutations in the KRAS oncogene and inactivating mutations/deletions in SMAD4 and TP53 tumor suppressor genes are significantly correlated with poor clinical outcomes in ICC 13, 16.